Important safety information
Tirzepatide injection
This summary does not replace the full prescribing information. Discuss any question with your physician. Compounded tirzepatide is not FDA-approved; FDA-approved tirzepatide products are Mounjaro® and Zepbound®.
Warning: risk of thyroid C-cell tumors
In studies with rodents, tirzepatide caused thyroid tumors, including thyroid cancer. It is not known whether tirzepatide causes thyroid tumors or medullary thyroid carcinoma (MTC) in people.
Do not use tirzepatide if you or any of your family have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your physician if you develop a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
Do not use tirzepatide if
You are allergic to tirzepatide or any of its ingredients, or you are using another GLP-1 receptor agonist medication.
Possible serious side effects
Inflammation of the pancreas (pancreatitis), low blood sugar (especially with insulin or sulfonylureas), serious allergic reactions, kidney problems, severe stomach problems, changes in vision in people with type 2 diabetes, gallbladder problems, and depression or thoughts of suicide. Stop using tirzepatide and seek medical help right away if you have symptoms of any of these.
Common side effects
The most common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain. These usually lessen over time as your body adjusts to each dose.
Before you start
Tell your physician about all your medical conditions and every medication you take.
Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Prime is not affiliated with or endorsed by Eli Lilly and Company.